Diligence memo · auto-generated · as of July 2, 2026
Plexiform Bioscience Inc.
Plexiform Bioscience Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Plexiform Bioscience Inc. operates in Pharmaceuticals, based in DOVER.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Plexiform Bioscience Inc. has raised $1.3M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.3M on 2024-12-03.
Most recent recorded round closed around 2024-12-03.
Valuation (modeled)modeled
Provath models Plexiform Bioscience Inc. at approximately $5.1M (range $1.0M–$12M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.53× the median modeled value of Seed Pharmaceuticals companies in 2022–2024 (50 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 19 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 22% of Pharmaceuticals peers (1610 compared).
Modeled value ranks above 9% of those peers.
Closest niche peers: Celeris Therapeutics, Inc., Oligomerix, Inc., 2A Biosciences, Inc., Myosin Therapeutics Inc., Eluciderm Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.